{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:33:36Z","timestamp":1790721216177,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06277-5","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T06:17:33Z","timestamp":1775715453000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Screening policy changes and prostate cancer epidemiology: 20-year trends in diagnosis, treatment, incidence, and mortality"],"prefix":"10.1007","volume":"44","author":[{"given":"Shuai","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaide","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-nong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"issue":"16","key":"6277_CR1","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","volume":"333","author":"R Raychaudhuri","year":"2025","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB (2025) Prostate cancer: a review. JAMA 333(16):1433\u20131446. https:\/\/doi.org\/10.1001\/jama.2025.0228","journal-title":"JAMA"},{"issue":"1","key":"6277_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"6277_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-024-02688-8","volume":"25","author":"FB Denijs","year":"2024","unstructured":"Denijs FB, Van Poppel H, Stenzl A et al (2024) PSA testing in primary care: is it time to change our practice? BMC Prim Care 25(1):436. https:\/\/doi.org\/10.1186\/s12875-024-02688-8","journal-title":"BMC Prim Care"},{"key":"6277_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.urology.2023.01.011","volume":"174","author":"DJ Peterson","year":"2023","unstructured":"Peterson DJ, Bhambhvani HP, Baird DRW, Li S, Eisenberg ML, Brooks JD (2023) Prosteria - national trends and outcomes of more frequent than guideline recommended prostate specific antigen screening. Urology 174:92\u201398. https:\/\/doi.org\/10.1016\/j.urology.2023.01.011","journal-title":"Urology"},{"issue":"2","key":"6277_CR5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","volume":"157","author":"VA Moyer","year":"2012","unstructured":"Moyer VA, U.S. Preventive Services Task Force (2012) Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 157(2):120\u2013134. https:\/\/doi.org\/10.7326\/0003-4819-157-2-201207170-00459","journal-title":"Ann Intern Med"},{"issue":"10","key":"6277_CR6","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1002\/ijc.70026","volume":"157","author":"UE Okwor","year":"2025","unstructured":"Okwor UE, Raitanen J, Talala K et al (2025) Risk factors for low-risk prostate cancer: a retrospective cohort study within the FinRSPC trial. Int J Cancer 157(10):2033\u20132040. https:\/\/doi.org\/10.1002\/ijc.70026","journal-title":"Int J Cancer"},{"issue":"4","key":"6277_CR7","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ijc.34731","volume":"154","author":"M Caruana","year":"2024","unstructured":"Caruana M, Gulati R, Etzioni R et al (2024) Benefits and harms of prostate specific antigen testing according to australian guidelines. Int J Cancer 154(4):648\u2013658. https:\/\/doi.org\/10.1002\/ijc.34731","journal-title":"Int J Cancer"},{"issue":"18","key":"6277_CR8","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","volume":"319","author":"DC Grossman","year":"2018","unstructured":"US Preventive Services Task Force, Grossman DC, Curry SJ et al (2018) Screening for prostate cancer: US preventive services task force recommendation statement. JAMA 319(18):1901\u20131913. https:\/\/doi.org\/10.1001\/jama.2018.3710","journal-title":"JAMA"},{"issue":"2","key":"6277_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.juro.2013.04.119","volume":"190","author":"HB Carter","year":"2013","unstructured":"Carter HB, Albertsen PC, Barry MJ et al (2013) Early detection of prostate cancer: AUA guideline. J Urol 190(2):419\u2013426. https:\/\/doi.org\/10.1016\/j.juro.2013.04.119","journal-title":"J Urol"},{"issue":"5","key":"6277_CR10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.6004\/jnccn.2016.0060","volume":"14","author":"PR Carroll","year":"2016","unstructured":"Carroll PR, Parsons JK, Andriole G et al (2016) NCCN guidelines insights: prostate cancer early detection, version 2.2016. J Natl Compr Canc Netw 14(5):509\u2013519. https:\/\/doi.org\/10.6004\/jnccn.2016.0060","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"6277_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.6004\/jnccn.2023.0014","volume":"21","author":"KA Moses","year":"2023","unstructured":"Moses KA, Sprenkle PC, Bahler C et al (2023) NCCN guidelines\u00ae insights: prostate cancer early detection, version 1.2023. J Natl Compr Canc Netw 21(3):236\u2013246. https:\/\/doi.org\/10.6004\/jnccn.2023.0014","journal-title":"J Natl Compr Canc Netw"},{"key":"6277_CR12","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2017006","volume":"39","author":"E Choi","year":"2017","unstructured":"Choi E, Lee S, Nhung BC et al (2017) Cancer mortality-to-incidence ratio as an indicator of cancer management outcomes in organization for economic cooperation and development countries. Epidemiol Health 39:e2017006. https:\/\/doi.org\/10.4178\/epih.e2017006","journal-title":"Epidemiol Health"},{"issue":"5","key":"6277_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.11869","volume":"5","author":"L Burgess","year":"2022","unstructured":"Burgess L, Aldrighetti CM, Ghosh A et al (2022) Association of the USPSTF grade D recommendation against prostate-specific antigen screening with prostate cancer-specific mortality. JAMA Netw Open 5(5):e2211869. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.11869","journal-title":"JAMA Netw Open"},{"key":"6277_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1201753","volume":"13","author":"G Kadeerhan","year":"2023","unstructured":"Kadeerhan G, Xue B, Wu XL, Chen WN, Wang DW (2023) Incidence trends and survival of metastatic prostate cancer with bone and visceral involvement: 2010\u20132019 surveillance, epidemiology, and end results. Front Oncol 13:1201753. https:\/\/doi.org\/10.3389\/fonc.2023.1201753","journal-title":"Front Oncol"},{"issue":"3","key":"6277_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s13167-020-00214-1","volume":"11","author":"R Kucera","year":"2020","unstructured":"Kucera R, Pecen L, Topolcan O et al (2020) Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions. EPMA J 11(3):399\u2013418. https:\/\/doi.org\/10.1007\/s13167-020-00214-1","journal-title":"EPMA J"},{"issue":"1","key":"6277_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.prnil.2020.06.002","volume":"9","author":"SH Jeong","year":"2021","unstructured":"Jeong SH, Raman JD (2021) Impact of the evolving United States Preventative Services Task Force policy statements on incidence and distribution of prostate cancer over 15 years in a statewide cancer registry. Prostate Int 9(1):12\u201317. https:\/\/doi.org\/10.1016\/j.prnil.2020.06.002","journal-title":"Prostate Int"},{"issue":"22","key":"6277_CR17","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1200\/JCO.2015.61.6532","volume":"33","author":"MW Drazer","year":"2015","unstructured":"Drazer MW, Huo D, Eggener SE (2015) National prostate cancer screening rates after the 2012 US preventive services task force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol Off J Am Soc Clin Oncol 33(22):2416\u20132423. https:\/\/doi.org\/10.1200\/JCO.2015.61.6532","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6277_CR18","unstructured":"Surveillance, epidemiology, and end results (SEER) program (www.seer.cancer.gov) SEER*Stat database. incidence - SEER research data, 17 registries, Nov 2024 Sub (2000\u20132022) - linked to county attributes - time dependent (1990\u20132023) income\/rurality, 1969\u20132023 counties, national cancer institute, DCCPS, surveillance research program, released April 2025, based on the November 2024 submission"},{"issue":"9","key":"6277_CR19","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.2105\/ajph.83.9.1289","volume":"83","author":"A Friede","year":"1993","unstructured":"Friede A, Reid JA, Ory HW (1993) CDC WONDER: a comprehensive on-line public health information system of the centers for disease control and prevention. Am J Public Health 83(9):1289\u20131294. https:\/\/doi.org\/10.2105\/ajph.83.9.1289","journal-title":"Am J Public Health"},{"issue":"10440","key":"6277_CR20","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"GBD 2021 Diseases and Injuries Collaborators","year":"2024","unstructured":"GBD 2021 Diseases and Injuries Collaborators (2024) Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet Lond Engl 403(10440):2133\u20132161. https:\/\/doi.org\/10.1016\/S0140-6736(24)00757-8","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"6277_CR21","first-page":"1","volume":"47","author":"RN Anderson","year":"1998","unstructured":"Anderson RN, Rosenberg HM (1998) Age standardization of death rates: implementation of the year 2000 standard. Natl Vital Stat Rep Cent Dis Control Prev Natl Cent Health Stat Natl Vital Stat Syst 47(3):1\u201316","journal-title":"Natl Vital Stat Rep Cent Dis Control Prev Natl Cent Health Stat Natl Vital Stat Syst"},{"issue":"7","key":"6277_CR22","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/(SICI)1097-0258(19970415)16:7<791::AID-SIM500>3.0.CO;2-#","volume":"16","author":"MP Fay","year":"1997","unstructured":"Fay MP, Feuer EJ (1997) Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med 16(7):791\u2013801","journal-title":"Stat Med"},{"issue":"10258","key":"6277_CR23","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet Lond Engl 396(10258):1204\u20131222. https:\/\/doi.org\/10.1016\/S0140-6736(20)30925-9","journal-title":"Lancet Lond Engl"},{"key":"6277_CR24","first-page":"1","volume":"20","author":"RJ Klein","year":"2001","unstructured":"Klein RJ, Schoenborn CA (2001) Age adjustment using the 2000 projected U.S. population. Healthy People 2010 Stat Notes Cent Dis Control Prev Cent Health Stat 20:1\u201310","journal-title":"Healthy People 2010 Stat Notes Cent Dis Control Prev Cent Health Stat"},{"issue":"6","key":"6277_CR25","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.juro.2017.05.074","volume":"198","author":"DJ Lee","year":"2017","unstructured":"Lee DJ, Mallin K, Graves AJ et al (2017) Recent changes in prostate cancer screening practices and epidemiology. J Urol 198(6):1230\u20131240. https:\/\/doi.org\/10.1016\/j.juro.2017.05.074","journal-title":"J Urol"},{"issue":"6","key":"6277_CR26","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/bju.15051","volume":"125","author":"KR Seetharam Bhat","year":"2020","unstructured":"Seetharam Bhat KR, Moschovas MC, Onol FF et al (2020) Trends in clinical and oncological outcomes of robot-assisted radical prostatectomy before and after the 2012 US preventive services task force recommendation against PSA screening: a decade of experience. BJU Int 125(6):884\u2013892. https:\/\/doi.org\/10.1111\/bju.15051","journal-title":"BJU Int"},{"issue":"3","key":"6277_CR27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00345-018-2396-2","volume":"37","author":"SR Leyh-Bannurah","year":"2019","unstructured":"Leyh-Bannurah SR, Karakiewicz PI, Pompe RS et al (2019) Inverse stage migration patterns in north American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations. World J Urol 37(3):469\u2013479. https:\/\/doi.org\/10.1007\/s00345-018-2396-2","journal-title":"World J Urol"},{"issue":"2","key":"6277_CR28","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/pros.24261","volume":"82","author":"BD Plambeck","year":"2022","unstructured":"Plambeck BD, Wang LL, Mcgirr S et al (2022) Effects of the 2012 and 2018 US preventive services task force prostate cancer screening guidelines on pathologic outcomes after prostatectomy. Prostate 82(2):216\u2013220. https:\/\/doi.org\/10.1002\/pros.24261","journal-title":"Prostate"},{"issue":"7","key":"6277_CR29","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/jnci\/djac066","volume":"114","author":"LD Borregales","year":"2022","unstructured":"Borregales LD, DeMeo G, Gu X et al (2022) Grade migration of prostate cancer in the united states during the last decade. J Natl Cancer Inst 114(7):1012\u20131019. https:\/\/doi.org\/10.1093\/jnci\/djac066","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"6277_CR30","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00345-016-1824-4","volume":"34","author":"NJ Kinnear","year":"2016","unstructured":"Kinnear NJ, Kichenadasse G, Plagakis S et al (2016) Prostate cancer in men aged less than 50 years at diagnosis. World J Urol 34(11):1533\u20131539. https:\/\/doi.org\/10.1007\/s00345-016-1824-4","journal-title":"World J Urol"},{"issue":"7","key":"6277_CR31","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamaoncol.2025.0963","volume":"11","author":"SM Monda","year":"2025","unstructured":"Monda SM, Demus T, Jaime-Casas S et al (2025) Trends in surgical overtreatment of prostate cancer. JAMA Oncol 11(7):700\u2013706. https:\/\/doi.org\/10.1001\/jamaoncol.2025.0963","journal-title":"JAMA Oncol"},{"issue":"2","key":"6277_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/s1040-8428(01)00187-1","volume":"42","author":"U Vaishampayan","year":"2002","unstructured":"Vaishampayan U, Hussain M (2002) The evolving role of systemic therapy in high risk prostate cancer: strategies for cure in the 21st century. Crit Rev Oncol Hematol 42(2):179\u2013188. https:\/\/doi.org\/10.1016\/s1040-8428(01)00187-1","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"6277_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-65354-0","volume":"14","author":"H Sherafatmandjoo","year":"2024","unstructured":"Sherafatmandjoo H, Safaei AA, Ghaderi F, Allameh F (2024) Prostate cancer diagnosis based on multi-parametric MRI, clinical and pathological factors using deep learning. Sci Rep 14(1):14951. https:\/\/doi.org\/10.1038\/s41598-024-65354-0","journal-title":"Sci Rep"},{"issue":"2","key":"6277_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102298","volume":"23","author":"N Aziz","year":"2025","unstructured":"Aziz N, Nabi W, Khan M et al (2025) Trends and disparities in prostate cancer mortality in the united states (1999\u20132020). Clin Genitourin Cancer 23(2):102298. https:\/\/doi.org\/10.1016\/j.clgc.2024.102298","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"6277_CR35","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1177\/1557988312473774","volume":"7","author":"S Antwi","year":"2013","unstructured":"Antwi S, Tucker TC, Coker AL, Fleming ST (2013) Racial disparities in survival after diagnosis of prostate cancer in Kentucky, 2001\u20132010. Am J Mens Health 7(4):306\u2013316. https:\/\/doi.org\/10.1177\/1557988312473774","journal-title":"Am J Mens Health"},{"issue":"1","key":"6277_CR36","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1177\/1524839904263682","volume":"7","author":"CK Gwede","year":"2006","unstructured":"Gwede CK, McDermott RJ (2006) Prostate cancer screening decision making under controversy: implications for health promotion practice. Health Promot Pract 7(1):134\u2013146. https:\/\/doi.org\/10.1177\/1524839904263682","journal-title":"Health Promot Pract"},{"issue":"11","key":"6277_CR37","doi-asserted-by":"publisher","first-page":"501.e1","DOI":"10.1016\/j.urolonc.2018.06.011","volume":"36","author":"OS Nettey","year":"2018","unstructured":"Nettey OS, Walker AJ, Keeter MK et al (2018) Self-reported black race predicts significant prostate cancer independent of clinical setting and clinical and socioeconomic risk factors. Urol Oncol 36(11):501.e1-501.e8. https:\/\/doi.org\/10.1016\/j.urolonc.2018.06.011","journal-title":"Urol Oncol"},{"issue":"4","key":"6277_CR38","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10552-021-01544-9","volume":"33","author":"RJ Wray","year":"2022","unstructured":"Wray RJ, Nicks SE, Adsul P et al (2022) Promoting informed prostate cancer screening decision-making for African American men in a community-based setting. Cancer Causes Control 33(4):503\u2013514. https:\/\/doi.org\/10.1007\/s10552-021-01544-9","journal-title":"Cancer Causes Control"},{"issue":"1","key":"6277_CR39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/cncr.34530","volume":"129","author":"P Riviere","year":"2023","unstructured":"Riviere P, Kalavacherla S, Banegas MP et al (2023) Patient perspectives of prostate cancer screening vary by race following 2018 guideline changes. Cancer 129(1):82\u201388. https:\/\/doi.org\/10.1002\/cncr.34530","journal-title":"Cancer"},{"issue":"3","key":"6277_CR40","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s13187-015-0871-7","volume":"31","author":"SK Frencher","year":"2016","unstructured":"Frencher SK, Sharma AK, Teklehaimanot S et al (2016) PEP talk: prostate education program, \u201ccutting through the uncertainty of prostate cancer for black men using decision support instruments in barbershops.\u201d J Cancer Educ 31(3):506\u2013513. https:\/\/doi.org\/10.1007\/s13187-015-0871-7","journal-title":"J Cancer Educ"},{"issue":"3","key":"6277_CR41","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/pcan.2014.23","volume":"17","author":"BA Mahal","year":"2014","unstructured":"Mahal BA, Aizer AA, Ziehr DR et al (2014) The association between insurance status and prostate cancer outcomes: implications for the affordable care act. Prostate Cancer Prostatic Dis 17(3):273\u2013279. https:\/\/doi.org\/10.1038\/pcan.2014.23","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"Suppl 2","key":"6277_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-6-S2-S10","volume":"6","author":"FT Odedina","year":"2011","unstructured":"Odedina FT, Dagne G, Pressey S et al (2011) Prostate cancer health and cultural beliefs of black men: The Florida prostate cancer disparity project. Infect Agent Cancer 6(Suppl 2):S10. https:\/\/doi.org\/10.1186\/1750-9378-6-S2-S10","journal-title":"Infect Agent Cancer"},{"issue":"1","key":"6277_CR43","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1186\/s12889-021-10793-x","volume":"21","author":"N Vapiwala","year":"2021","unstructured":"Vapiwala N, Miller D, Laventure B et al (2021) Stigma, beliefs and perceptions regarding prostate cancer among black and latino men and women. BMC Public Health 21(1):758. https:\/\/doi.org\/10.1186\/s12889-021-10793-x","journal-title":"BMC Public Health"},{"issue":"6","key":"6277_CR44","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.21037\/jtd-21-87","volume":"13","author":"S Singh","year":"2021","unstructured":"Singh S, Sridhar P (2021) A narrative review of sociodemographic risk and disparities in screening, diagnosis, treatment, and outcomes of the most common extrathoracic malignancies in the United States. J Thorac Dis 13(6):3827\u20133843. https:\/\/doi.org\/10.21037\/jtd-21-87","journal-title":"J Thorac Dis"},{"issue":"34","key":"6277_CR45","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.1200\/JCO.23.00864","volume":"41","author":"F Kamangar","year":"2023","unstructured":"Kamangar F, Dores GM, Anderson WF (2023) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 41(34):5209\u20135224. https:\/\/doi.org\/10.1200\/JCO.23.00864","journal-title":"J Clin Oncol"},{"issue":"1","key":"6277_CR46","doi-asserted-by":"publisher","first-page":"e2456825","DOI":"10.1001\/jamanetworkopen.2024.56825","volume":"8","author":"EL Van Blarigan","year":"2025","unstructured":"Van Blarigan EL, McKinley MA, Washington SL et al (2025) Trends in prostate cancer incidence and mortality rates. JAMA Netw Open 8(1):e2456825. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.56825","journal-title":"JAMA Netw Open"},{"issue":"3","key":"6277_CR47","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","volume":"87","author":"EJ Schafer","year":"2025","unstructured":"Schafer EJ, Laversanne M, Sung H et al (2025) Recent patterns and trends in global prostate cancer incidence and mortality: an update. Eur Urol 87(3):302\u2013313. https:\/\/doi.org\/10.1016\/j.eururo.2024.11.013","journal-title":"Eur Urol"},{"key":"6277_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-077738","volume":"386","author":"S Vaccarella","year":"2024","unstructured":"Vaccarella S, Li M, Bray F et al (2024) Prostate cancer incidence and mortality in Europe and implications for screening activities: population based study. BMJ 386:e077738. https:\/\/doi.org\/10.1136\/bmj-2023-077738","journal-title":"BMJ"},{"issue":"8","key":"6277_CR49","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3390\/curroncol32080426","volume":"32","author":"M Taborelli","year":"2025","unstructured":"Taborelli M, Serraino D, Toffolutti F et al (2025) Trends in prostate cancer incidence and survival by Gleason score from 2000 to 2020: a population-based study in Northeastern Italy. Curr Oncol 32(8):426. https:\/\/doi.org\/10.3390\/curroncol32080426","journal-title":"Curr Oncol"},{"key":"6277_CR50","doi-asserted-by":"publisher","first-page":"102931","DOI":"10.1016\/j.canep.2025.102931","volume":"99","author":"ACCS de Santana","year":"2025","unstructured":"de Santana ACCS, Santos ESR, Batista JFC et al (2025) Temporal trends and Spatial distribution of prostate cancer incidence and mortality in a Northeastern Brazilian state. Cancer Epidemiol 99:102931. https:\/\/doi.org\/10.1016\/j.canep.2025.102931","journal-title":"Cancer Epidemiol"},{"key":"6277_CR51","doi-asserted-by":"publisher","first-page":"j5757","DOI":"10.1136\/bmj.j5757","volume":"360","author":"TM Seibert","year":"2018","unstructured":"Seibert TM, Fan CC, Wang Y et al (2018) Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ 360:j5757. https:\/\/doi.org\/10.1136\/bmj.j5757","journal-title":"BMJ"},{"issue":"2","key":"6277_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11020354","volume":"11","author":"OS T\u0103taru","year":"2021","unstructured":"T\u0103taru OS, Vartolomei MD, Rassweiler JJ et al (2021) Artificial intelligence and machine learning in prostate cancer patient management-current trends and future perspectives. Diagnostics 11(2):354. https:\/\/doi.org\/10.3390\/diagnostics11020354","journal-title":"Diagnostics"},{"issue":"10071","key":"6277_CR53","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet Lond Engl 389(10071):815\u2013822. https:\/\/doi.org\/10.1016\/S0140-6736(16)32401-1","journal-title":"Lancet Lond Engl"},{"issue":"10","key":"6277_CR54","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1093\/aje\/kwab155","volume":"190","author":"N Hendrix","year":"2021","unstructured":"Hendrix N, Gulati R, Jiao B, Kader AK, Ryan ST, Etzioni R (2021) Clarifying the trade-offs of risk-stratified screening for prostate cancer: a cost-effectiveness study. Am J Epidemiol 190(10):2064\u20132074. https:\/\/doi.org\/10.1093\/aje\/kwab155","journal-title":"Am J Epidemiol"},{"issue":"2","key":"6277_CR55","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41391-024-00884-2","volume":"28","author":"O Windisch","year":"2025","unstructured":"Windisch O, Valerio M, Yee CH et al (2025) Biopsy strategies in the era of mpMRI: a comprehensive review. Prostate Cancer Prostatic Dis 28(2):288\u2013297. https:\/\/doi.org\/10.1038\/s41391-024-00884-2","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"6277_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126266","volume":"22","author":"B Pastor-Navarro","year":"2021","unstructured":"Pastor-Navarro B, Rubio-Briones J, Borque-Fernando \u00c1, Esteban LM, Dominguez-Escrig JL, L\u00f3pez-Guerrero JA (2021) Active surveillance in prostate cancer: role of available biomarkers in daily practice. Int J Mol Sci 22(12):6266. https:\/\/doi.org\/10.3390\/ijms22126266","journal-title":"Int J Mol Sci"},{"issue":"11","key":"6277_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70979","volume":"14","author":"C Cobbs","year":"2025","unstructured":"Cobbs C, Chesnut GT, Shafi AA (2025) Understanding racial disparities in prostate cancer: a multifaceted approach. Cancer Med 14(11):e70979. https:\/\/doi.org\/10.1002\/cam4.70979","journal-title":"Cancer Med"},{"key":"6277_CR58","doi-asserted-by":"publisher","first-page":"107737","DOI":"10.1016\/j.cct.2024.107737","volume":"147","author":"J Neil","year":"2024","unstructured":"Neil J, Mao B, Shao R et al (2024) A pilot randomized clinical trial of a smartphone-based application to support at-home PSA screening and culturally tailored prostate cancer education for African American men: a study protocol. Contemp Clin Trials 147:107737. https:\/\/doi.org\/10.1016\/j.cct.2024.107737","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"6277_CR59","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/cncr.26315","volume":"118","author":"MJ Hall","year":"2012","unstructured":"Hall MJ, Ruth K, Giri VN (2012) Rates and predictors of colorectal cancer screening by race among motivated men participating in a prostate cancer risk assessment program. Cancer 118(2):478\u2013484. https:\/\/doi.org\/10.1002\/cncr.26315","journal-title":"Cancer"},{"issue":"18","key":"6277_CR60","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.2018.3712","volume":"319","author":"JJ Fenton","year":"2018","unstructured":"Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J (2018) Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US preventive services task force. JAMA 319(18):1914\u20131931. https:\/\/doi.org\/10.1001\/jama.2018.3712","journal-title":"JAMA"},{"issue":"2","key":"6277_CR61","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB et al (2016) The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40(2):244\u2013252. https:\/\/doi.org\/10.1097\/PAS.0000000000000530","journal-title":"Am J Surg Pathol"},{"issue":"19","key":"6277_CR62","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378(19):1767\u20131777. https:\/\/doi.org\/10.1056\/NEJMoa1801993","journal-title":"N Engl J Med"},{"issue":"6","key":"6277_CR63","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1001\/jamaoncol.2021.0884","volume":"7","author":"RC Chen","year":"2021","unstructured":"Chen RC, Haynes K, Du S, Barron J, Katz AJ (2021) Association of cancer screening deficit in the united States with the COVID-19 pandemic. JAMA Oncol 7(6):878\u2013884. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0884","journal-title":"JAMA Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06277-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06277-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06277-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T06:17:38Z","timestamp":1775715458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06277-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6277"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06277-5","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"8 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Publicly available, de-identified aggregate data were used; no human subjects were involved. Ethics review and consent were not required under institutional policy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"288"}}